EMA Authorised: Thalidomide Lipomed (thalidomide) — Lipomed GmbH

View source ↗

Summary

The European Medicines Agency authorised Thalidomide Lipomed (thalidomide) by Lipomed GmbH for use in multiple myeloma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Thalidomide Lipomed (thalidomide)

Snippet

Status: Authorised. Therapeutic area: Multiple Myeloma. MAH: Lipomed GmbH. Decision date: 10/05/2024